Skip to main navigation Skip to search Skip to main content

Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer

  • Keith M. Kerr
  • , Lukas Bubendorf
  • , Martin J. Edelman
  • , Antonio Marchetti
  • , Tony Mok
  • , Silvia Novello
  • , Ken O'Byrne
  • , Rolf Stahel
  • , Solange Peters
  • , Enriqueta Felip
  • , Benjamin Besse
  • , Johan Vansteenkiste
  • , Wilfried Eberhardt
  • , Paul Baas
  • , Martin Reck
  • , Konstantinos Syrigos
  • , Luis Paz-Ares
  • , Egbert F. Smit
  • , Peter Meldgaard
  • , Alex Adjei
  • Marianne Nicolson, Lucio Crinò, Paul Van Schil, Suresh Senan, Corinne Faivre-Finn, Gaetano Rocco, Giulia Veronesi, Jean Yves Douillard, Eric Lim, Christophe Dooms, Walter Weder, Dirk de Ruysscher, Cecile Le Pechoux, Paul de Leyn, Virginie Westeel
  • University of Aberdeen
  • University of Basel
  • University of New Mexico
  • Gabriele d'Annunzio University
  • The Chinese University of Hong Kong
  • Azienda Ospedaliera S. Luigi Gonzaga
  • Trinity College Dublin
  • Queensland University of Technology
  • University of Zurich
  • University of Lausanne
  • University Hospital Vall d’Hebron
  • Université Paris-Sud
  • KU Leuven
  • University of Duisburg-Essen
  • Antoni van Leeuwenhoek Hospital
  • Krankenhaus Grosshansdorf
  • Athens Chest Hospital Sotiria
  • Hospital Universitario Virgen del Rocio
  • VU University Medical Center
  • Aarhus University
  • Roswell Park Cancer Institute
  • NHS Grampian
  • University Hospital of Perugia
  • University of Antwerp
  • The Christie NHS Foundation Trust
  • IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
  • IRCCS Istituto Europeo di Oncologia - Milano
  • Royal Brompton Hospital
  • Université de Franche-Comté
  • University of Nantes

Research output: Contribution to journalArticlepeer-review

267 Scopus citations

Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with nonsmall- cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.

Original languageEnglish
Pages (from-to)1681-1690
Number of pages10
JournalAnnals of Oncology
Volume25
Issue number9
DOIs
StatePublished - Sep 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Consensus
  • ESMO
  • Molecular testing
  • Non-small-cell lung cancer
  • Pathology
  • Recommendations

Fingerprint

Dive into the research topics of 'Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this